A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias.

Saved in:
Bibliographic Details
Title: A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias.
Authors: Senapati J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA.; Department of Medical Oncology, Montefiore Einstein Cancer Center, New York, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., DiNardo C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Deshmukh I; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Alvarez J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Tang G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Abbas HA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Bhalla K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Midde NM; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Said N; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Noyalis A; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Mires DE; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Ning J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA., Xiao L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA. ndaver@mdanderson.org.
Source: Journal of hematology & oncology [J Hematol Oncol] 2025 Nov 27; Vol. 18 (1), pp. 108. Date of Electronic Publication: 2025 Nov 27.
Publication Type: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1756-8722
DOI:10.1186/s13045-025-01757-4